Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

PT-141

Bremelanotide, Vyleesi

Quick Stats
Studies 74
Trials 10
Score 3
2023 pubmed 4 citations

What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder.

de Oliveira. Leonor L; Vignozzi. Linda L; Giraldi. Annamaria A; Varod. Shelly S; Corona. Giovanni G; Reisman. Yacov Y

Key Findings

  • HSDD affects about 28% of premenopausal women with sexual dysfunction.
  • Bremelanotide (pt‑141) and flibanserin are the only US‑approved drugs for HSDD; none are approved in Europe yet.
  • Combining medical (e.g., pt‑141) and psychological approaches yields better outcomes than either alone.

Practical Outcomes

  • For biohackers, pt‑141 is an approved option in the US and may help when paired with counseling or self‑guided therapy. Expect limited access in Europe and consider personal factors (mental health, relationship dynamics) before using it. Monitoring response and side effects is essential for safe self‑experimentation.

Summary

The review says that low sexual desire in young women is complex, involving biology, mind, and social factors, and that the only approved drugs in the US are flibanserin and bremelanotide (pt‑141). It stresses that combining medication with therapy works best, but doctors still debate using drugs for younger women, and many women want more treatment options.

Abstract

Hypoactive sexual desire disorder (HSDD) in premenopausal women involves biological, psychological, and social aspects. In the European Society for Sexual Medicine meeting in Rotterdam in February 2023, several leading experts in the field discussed the multifaceted nature of this disorder and the state of the art regarding treatment at a round table. This review reflects the information discussed at this event and further discusses current controversies. HSDD is the most prevalent female-estimated sexual disorder reported by 28% of the 40% premenopausal women with sexual dysfunction. Flibanserin and bremelanotide are the only approved medications to treat HSDD in the USA, and none are approved in Europe. Lybrido, Lybridos, and Lorexys are under development. There are several psychological factors with impact in sexual desire, including depression and sexual abuse. Feminine sexual scripts, the pleasure gap, and structural inequalities also affect sexual desire. Evidence strongly supports the value of combining medical and psychological approaches in the treatment of HSDD, but there is ongoing controversy regarding the pharmacological treatment of young women with HSDD. However, some women seem open and would like to have access to drug treatment. The treatment of HSDD in young women requires a mixed treatment approach that addresses the disorder's complexity. Despite clinicians seeming to be divided between using pharmacological and/or psychosocial approaches, some women might respond better to one type of intervention over the others. This calls for the development of tools that assess the best approach for each person, including their will and informed choice.

Study Information

Provider

pubmed

Year

2023

Date

2023-12-27T00:00:00.000Z

DOI

10.1159/000535587

Citations

4

References

79